OCB Drug Testing Guidelines

Policy on Prescribed Testosterone

OCB handles theraputic use exemptions for prescribed testosterone due to androgen deficiency in the manner that the World Anti-Doping Agency (WADA) does.

 

Exemptions are possible in cases where there's a pathological physical change in the structure of an organ or within the hypothalamic-pituitary-testicular axis, such as:

  • Genetic abnormalities – Isolated hypogonadotropic hypogonadism (IHH) and variants, Klinefelter’s Syndrome and variants (i.e. 47,XYY/46XY, 46,XX testicular DSD, 45,X/46,XY), dysgenetic testes, myotonic dystrophy.
  • Developmental abnormalities – cryptorchidism, congenital anorchia.
  • Metabolic abnormalities – hemochromatosis.
  • Direct testicular trauma, surgical bilateral orchidectomy, testicular torsion.
  • Orchitis – severe bilateral with subsequent testicular atrophy due to mumps or other infections.
  • Radiation treatment or chemotherapy.
  • Pituitary disorders – hypopituitarism, tumor, infection, hemochromatosis, hyperprolactinemia due to prolactin-secreting pituitary tumor.
  • Structural and infiltrative effects of systemic diseases – CNS developmental abnormalities, infection, β-thalassemia/hemoglobinopathies, granulomatous diseases, lymphocytic hypophysitis hemochromatosis, sickle cell disease.
  • Anatomical problems - pituitary stalk section, hypophysectomy, pituitary-hypothalamic disease, traumatic brain injury.

Exemptions are not made in cases where there is no pathological physical change in the structure of an organ or within the hypothalamic-pituitary-testicular axis, such as:

  • Overtraining, malnutrition/nutritional deficiency.
  • Chronic systemic illness (chronic organ failure, diabetes mellitus, malignancy, rheumatic disease, HIV infection, Crohn’s disease, inherited metabolic storage diseases).
  • Aging/Late onset hypogonadism.